Alnylam Seeks Deals As RNAi Interest Heats Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Company looking to build on current deals with Merck and Novartis, COO says in interview with "The Pink Sheet" DAILY.
You may also be interested in...
Alnylam Ends Relationship With Sirna Owner Merck
RNAi firm Alnylam terminated the relationship “to protect our intellectual property,” COO Greene tells “The Pink Sheet” DAILY.
Alnylam Ends Relationship With Sirna Owner Merck
RNAi firm Alnylam terminated the relationship “to protect our intellectual property,” COO Greene tells “The Pink Sheet” DAILY.
Alnylam Signs Billion Dollar RNAi Deal With Roche
Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.